139 related articles for article (PubMed ID: 37926541)
41. Combined crystal-storing histiocytosis, light chain proximal tubulopathy, and light chain crystalline podocytopathy in a patient with multiple myeloma: a case report and literature review.
Zhu L; Wang L; Shi H; Jiang L; Li X; Shao C; Yan Y; Dong B; Zou W; Zuo L
Ren Fail; 2023 Dec; 45(1):2145970. PubMed ID: 36632756
[TBL] [Abstract][Full Text] [Related]
42. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients.
Rota S; Mougenot B; Baudouin B; De Meyer-Brasseur M; Lemaitre V; Michel C; Mignon F; Rondeau E; Vanhille P; Verroust P
Medicine (Baltimore); 1987 Mar; 66(2):126-37. PubMed ID: 3102893
[TBL] [Abstract][Full Text] [Related]
43. The role of immunological assessment in patients with acute kidney injury and possible myeloma.
Lachmann HJ; Wassef NL
Adv Chronic Kidney Dis; 2012 Sep; 19(5):287-90. PubMed ID: 22920638
[TBL] [Abstract][Full Text] [Related]
44. Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury.
Steiner N; Abdel Hamid A; Kronbichler A; Neuwirt H; Myslivecek M; Kollar M; Lachmanova J; Rysava R; Hruskova Z; Spicka I; Willenbacher W; Nachbaur D; Wolf D; Tesar V; Gunsilius E
J Nephrol; 2021 Aug; 34(4):1263-1270. PubMed ID: 33382447
[TBL] [Abstract][Full Text] [Related]
45. Plasma exchange combined with bortezomib-based chemotherapy is effective for early renal recovery in a patient with IgD-λ type multiple myeloma.
Ueda H; Kuno H; Takahashi D; Katsuma A; Kimura A; Nakashima A; Kato J; Momoki M; Ohba R; Dobashi N; Yamamoto I; Kawamura T; Miyazaki Y; Yokoo T
CEN Case Rep; 2020 May; 9(2):165-172. PubMed ID: 31974826
[TBL] [Abstract][Full Text] [Related]
46. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.
Hutchison CA; Batuman V; Behrens J; Bridoux F; Sirac C; Dispenzieri A; Herrera GA; Lachmann H; Sanders PW;
Nat Rev Nephrol; 2011 Nov; 8(1):43-51. PubMed ID: 22045243
[TBL] [Abstract][Full Text] [Related]
47. Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy.
Huang ZQ; Sanders PW
Lab Invest; 1995 Dec; 73(6):810-7. PubMed ID: 8558842
[TBL] [Abstract][Full Text] [Related]
48. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.
Peters NO; Laurain E; Cridlig J; Hulin C; Cao-Huu T; Frimat L
Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823
[TBL] [Abstract][Full Text] [Related]
49. Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report.
Donati G; Zappulo F; Croci Chiocchini AL; Comai G; Zamagni E; La Manna G
Hemodial Int; 2019 Jul; 23(3):E97-E99. PubMed ID: 30791209
[TBL] [Abstract][Full Text] [Related]
50. [IgD myeloma manifesting as acute renal insufficiency].
Duvic C; Sarret D; De Revel T; Hérody M; Didelot F; Labaye J; Nédélec G
Rev Med Interne; 2000 Sep; 21(9):799-803. PubMed ID: 11039177
[TBL] [Abstract][Full Text] [Related]
51. [Serum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy and light chain deposition disease].
Honma R; Fukase S; Suzuki M; Omoto E
Rinsho Ketsueki; 2010 Apr; 51(4):270-4. PubMed ID: 20467224
[TBL] [Abstract][Full Text] [Related]
52. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
53. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
[TBL] [Abstract][Full Text] [Related]
54. [Morphological and immunohistochemical predictors of renal response to therapy patients with myeloma cast nephropathy and dialysis-dependent acute kidney injury].
Rekhtina IG; Kazarina EV; Stolyarevich ES; Kovrigina AM; Dvirnyk VN; Kulikov SM; Mendeleeva LP
Ter Arkh; 2020 Sep; 92(7):63-69. PubMed ID: 33346446
[TBL] [Abstract][Full Text] [Related]
55. Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy.
Snozek CLH; Kinard TN; Adamski J
J Clin Apher; 2018 Jun; 33(3):439-443. PubMed ID: 29427353
[TBL] [Abstract][Full Text] [Related]
56. A case of acute renal failure with multiple origins of the renal injury.
Micarelli D; Cristi E; Taddei AR; Rovere FRD; Mercanti C; Feriozzi S
CEN Case Rep; 2020 Nov; 9(4):437-441. PubMed ID: 32623690
[TBL] [Abstract][Full Text] [Related]
57. Crystalline cast nephropathy in a patient with IgD lambda myeloma.
Kumakura S; Nakaya I; Sakuma T; Sato H; Soma J
Clin Exp Nephrol; 2016 Jun; 20(3):491-2. PubMed ID: 26515717
[No Abstract] [Full Text] [Related]
58. [Management of Cast Nephropathy].
De Simone E; Fenoglio R; Cortazzi S; Careddu A; Geraci G; Bugliosi F; Sciascia S; Roccatello D
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007838
[TBL] [Abstract][Full Text] [Related]
59. Current approach to diagnosis and management of acute renal failure in myeloma patients.
Leung N; Behrens J
Adv Chronic Kidney Dis; 2012 Sep; 19(5):297-302. PubMed ID: 22920640
[TBL] [Abstract][Full Text] [Related]
60. Crystalglobulin-associated nephropathy presenting as MGRS in a case of monoclonal B-cell lymphocytosis: a case report.
Gupta RK; Arend LJ; Bk A; Narsipur S; Bhargava R
BMC Nephrol; 2020 May; 21(1):184. PubMed ID: 32423442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
